共 73 条
[1]
Siegel RL(2017)Cancer statistics, 2017 CA Cancer J Clin 67 7-30
[2]
Miller KD(2015)Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers BMC Med 13 1-6
[3]
Jemal A(2005)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687-1717
[4]
Migliaccio I(2017)3rd ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 3) Ann Oncol 28 16-33
[5]
Malorni L(2016)Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline J Clin Oncol 34 3069-3103
[6]
Hart CD(2012)Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer N Engl J Med 366 520-529
[7]
Guarducci C(2015)Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer J Hematol Oncol 8 98-1079
[8]
Di Leo A(2010)Driving the cell cycle with a minimal CDK control network Nature 468 1074-1569
[9]
Cardoso F(2017)Recent advances of highly selective CDK4/6 inhibitors in breast cancer J Hematol Oncol 10 97-1514
[10]
Costa A(2017)A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer Curr Med Res Opin 33 1559-247